October 22, 2019
Takeda gets license for Celiac Disease therapy from COUR Pharmaceuticals after positive phase 2a proof-of-concept study
Takeda got exclusive global license for investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in…